InvestSMART

Emyria Limited (ASX: EMD) - Announcements

Current share price for EMD : $0.047 0.001 (2.17%)+

ASX company news and announcements for Emyria Limited (EMD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Emyria Limited (EMD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Emyria Limited (EMD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Emyria Limited (EMD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$38 Notice under section 708A(5)(e) of the Corporations Act 27 Feb 2023 8:02AM $0.215 $0.047 fallen by 78.14%
$38 Half Yearly Report and Accounts 27 Feb 2023 8:02AM $0.215 $0.047 fallen by 78.14%
$38 Investor Presentation 24 Feb 2023 12:34PM $0.220 $0.047 fallen by 78.64%
$38 Change of Director's Interest Notice x 5 23 Feb 2023 5:09PM $0.225 $0.047 fallen by 79.11%
$38 Notification regarding unquoted securities - EMD 23 Feb 2023 5:06PM $0.225 $0.047 fallen by 79.11%
$38 Application for quotation of securities - EMD 23 Feb 2023 5:03PM $0.225 $0.047 fallen by 79.11%
$38 Emyria secures clinical-grade MDMA supply for Aust patients 13 Feb 2023 9:33AM $0.245 $0.047 fallen by 80.82%
$38 Emyria expands MDMA programs following landmark TGA decision 6 Feb 2023 9:25AM $0.190 $0.047 fallen by 75.26%
$38 Appendix 4C - Quarterly 31 Jan 2023 9:28AM $0.170 $0.047 fallen by 72.35%
$38 Change in substantial holding SW 31 Jan 2023 9:18AM $0.170 $0.047 fallen by 72.35%
$38 First dosing commenced for pivotal EMD-RX5 Phase 3 trial 30 Jan 2023 9:37AM $0.165 $0.047 fallen by 71.52%
$38 Results of Meeting 25 Jan 2023 6:04PM $0.160 $0.047 fallen by 70.63%
$38 Emyria receives $2.1M R&D tax incentive refund 12 Jan 2023 9:41AM $0.170 $0.047 fallen by 72.35%
$38 Biotech Showcase San Francisco Presentation 10 Jan 2023 9:28AM $0.175 $0.047 fallen by 73.14%
$38 Notification of cessation of securities - EMD 5 Jan 2023 9:49AM $0.175 $0.047 fallen by 73.14%
$38 Letter to Shareholders/Notice of General Meeting/Proxy Form 16 Dec 2022 1:11PM $0.185 $0.047 fallen by 74.59%
$38 Notice under section 708A(5)(e) of the Corporations Act 7 Dec 2022 6:24PM $0.190 $0.047 fallen by 75.26%
$38 Application for quotation of securities - EMD 7 Dec 2022 6:18PM $0.190 $0.047 fallen by 75.26%
$38 Upcoming Emyria CEO Webinars 7 Dec 2022 9:17AM $0.185 $0.047 fallen by 74.59%
$38 Emyria accepted into National Institutes of Health Program 28 Nov 2022 9:07AM $0.190 $0.047 fallen by 75.26%
$38 Change of Director's Interest Notice 28 Nov 2022 8:15AM $0.190 $0.047 fallen by 75.26%
$38 Notification regarding unquoted securities - EMD 25 Nov 2022 12:16PM $0.190 $0.047 fallen by 75.26%
$38 Notification regarding unquoted securities - EMD 25 Nov 2022 12:09PM $0.190 $0.047 fallen by 75.26%
$38 Placement completion and secondary trading notice 23 Nov 2022 10:00AM $0.185 $0.047 fallen by 74.59%
$38 Investor Presentation 23 Nov 2022 9:55AM $0.185 $0.047 fallen by 74.59%

276 - 300 of 553 results

Page 12 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.